Join the Family Office Networks’ Webinar Series featuring Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
A Public Health Solutions business segment, funded entirely by the US Government to the amount of approximately $70 million to date, developing vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, emerging and antibiotic resistant infectious disease, and viral disease including Ebola, Marburg and COVID-19.
Nasdaq: SNGX Stock Snapshot as of 01/22/21 Market Cap: ~ $61 Million Stock Price: $1.72 Avg Daily Vol (50D): ~ 2.3 Million
Shares Outstanding: ~ 35.5 Million
